About: Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B‐cells due to treatment with rituximab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B‐cells due to treatment with rituximab Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B‐cells due to treatment with rituximab
Creator	Fallet, Benedict Kyburz, Diego Rheumatology, Ulrich, A Walker, Walker, Ulrich
source	Medline; PMC
abstract	Over 4 million cases of Coronavirus disease 2019 (COVID‐19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been confirmed worldwide. Up to 20% of cases develop severe disease and the fatality rate are high.[1] Little is known however on the course of the infection in immunosuppressed patients. We therefore report the case of a patient with COVID‐19 under immunosuppression with rituximab. This 77‐year‐old woman was admitted to the hospital with a 5‐week history of unclear fever (up to 38.5°C), hypotension (80 mmHg systolic on self‐measurement), occasional mild shortness of breath and intermittent dry cough.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1002/art.41380
bibo:pmid	32458534
has license	no-cc
sha1sum (hex)	100c5214f7e05746fa9a6e4c3189cb747400a429
schema:url	https://doi.org/10.1002/art.41380
resource representing a document's title	Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B‐cells due to treatment with rituximab
has PubMed Central identifier	PMC7283641
has PubMed identifier	32458534
schema:publication	Arthritis Rheumatol
resource representing a document's body	covid:100c5214f7e05746fa9a6e4c3189cb747400a429#body_text
is schema:about of	named entity 'virus' named entity 'antibodies' named entity 'critical role' named entity 'peripheral blood' named entity 'organ' named entity 'computed tomography (CT) scan' named entity 'antibody' named entity 'T-cell' named entity 'rituximab' named entity 'time-lapse' named entity 'COVID' named entity 'afebrile' named entity 'organ damage' named entity 'antibody response' named entity 'antibodies' named entity 'prednisone' named entity 'comorbidities' named entity 'SARS-CoV-2' named entity 'oxygen saturation' named entity 'viremia' named entity 'COVID' named entity 'fatigue' named entity 'immunosuppression' named entity 'blood pressure' named entity 'alveolitis' named entity 'Coronavirus' named entity 'COVID' named entity 'rRT-PCR' named entity 'mmHg' named entity 'EDI' named entity 'body temperature' named entity 'methotrexate' named entity 'elevated body temperature' named entity 'amoxicillin-clavulanic acid' named entity 'pantoprazole' named entity 'serological testing' named entity 'hypercholesterolemia' named entity 'lung' named entity 'B-cells' named entity 'peripheral blood' named entity 'nasopharyngeal swabs' named entity 'viral antigens' named entity 'rituximab' named entity 'coronavirus 2' named entity 'SARS-CoV-2' named entity 'rituximab' named entity 'immunosuppression' named entity 'SARS-CoV-2' named entity 'hypotension' named entity 'infusion' named entity 'rRT-PCR' named entity 'proteinase-3' named entity 'IgG' named entity 'osteoporosis' named entity 'immunosuppressed' named entity 'antiviral' named entity 'hypotension' named entity 'viral load' named entity 'sinusitis' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'B-cell' named entity 'autoantibody' named entity 'false positive' named entity 'fever' named entity 'antiviral' named entity 'COVID-19' named entity 'antiviral' named entity 'infection' named entity 'fatality rate' named entity '20%' named entity 'clinical examination' named entity 'infection' named entity 'folic acid' named entity 'lung edema' named entity 'otitis media'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software